MedTrace Logo

Efficacy of High Flow Therapy in COPD At Home

NCT02230020 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 8

Last updated 2017-08-08

No results posted yet for this study

Summary

Preliminary data show that in COPD patients, HFT substantially decreases ventilatory demand during sleep. The central hypothesis of this proposal is that lowering ventilatory demand using nasal high-flow therapy during sleep will elevate lung function, reduce dyspnea on exertion and improve quality of life. Thus, this proposal aims will determine the effects HFT over time on 1) lung function; 2) dyspnea on exertion; and 3) quality of life.

Conditions

Interventions

DEVICE

Nasal High Flow

Sponsors & Collaborators

Principal Investigators

  • Jason Kirkness, PhD · Johns Hopkins University

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-15
Primary Completion
2015-12-13
Completion
2015-12-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02230020 on ClinicalTrials.gov